My Treatment Approach: HER2+ Breast Cancer - Episode 7
TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting
Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.
Video content above is prompted by the following questions:
- For patients who progress through multiple HER2-targeted therapies, when would you consider chemotherapy and what specific regimens?
- Are there data supporting the use of continuing HER2 blockade with chemotherapy in later lines?
Related Content:
